Literature DB >> 21960592

MicroRNA profiles of t(14;18)-negative follicular lymphoma support a late germinal center B-cell phenotype.

Ellen Leich1, Alberto Zamo, Heike Horn, Eugenia Haralambieva, Bernhard Puppe, Randy D Gascoyne, Wing-Chung Chan, Rita M Braziel, Lisa M Rimsza, Dennis D Weisenburger, Jan Delabie, Elaine S Jaffe, Jude Fitzgibbon, Louis M Staudt, Hans-Konrad Mueller-Hermelink, Mariarita Calaminici, Elias Campo, German Ott, Luis Hernández, Andreas Rosenwald.   

Abstract

A total of 90% of follicular lymphomas (FLs) harbor the translocation t(14;18) leading to deregulated BCL2 expression. Conversely, 10% of FLs lack the t(14;18), and the majority of these FLs do not express BCL2. The molecular features of t(14;18)-negative FLs remain largely unknown. We performed microRNA expression analysis in 32 FL grades 1 to 3A, including 17 t(14;18)-positive FLs, 9 t(14;18)-negative FLs without BCL2 expression, and 6 t(14;18)-negative FLs with BCL2 expression. MicroRNA profiles were correlated with corresponding mRNA expression patterns, and potential targets were investigated by quantitative PCR and immunohistochemistry in an independent validation series of 83 FLs. Statistical analysis identified 17 microRNAs that were differentially expressed between t(14;18)-positive FLs and t(14;18)-negative FLs. The down-regulation of miR-16, miR-26a, miR-101, miR-29c, and miR138 in the t(14;18)-negative FL subset was associated with profound mRNA expression changes of potential target genes involving cell cycle control, apoptosis, and B-cell differentiation. miR-16 target CHEK1 showed increased expression in t(14;18)-negative FLs, whereas TCL1A expression was reduced, in line with a partial loss of the germinal center B-cell phenotype in this FL subset. In conclusion, t(14;18)-negative FL have distinct microRNA profiles that are associated with an increased proliferative capacity and a "late" germinal center B-cell phenotype.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21960592      PMCID: PMC3217356          DOI: 10.1182/blood-2011-06-361972

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  36 in total

1.  The protooncogene TCL1 is an Akt kinase coactivator.

Authors:  J Laine; G Künstle; T Obata; M Sha; M Noguchi
Journal:  Mol Cell       Date:  2000-08       Impact factor: 17.970

2.  MicroRNA-101 exerts tumor-suppressive functions in non-small cell lung cancer through directly targeting enhancer of zeste homolog 2.

Authors:  Ji-Guang Zhang; Jian-Feng Guo; Dong-Lei Liu; Quan Liu; Jian-Jun Wang
Journal:  J Thorac Oncol       Date:  2011-04       Impact factor: 15.609

3.  New hope for a microRNA therapy for liver cancer.

Authors:  John J Rossi
Journal:  Cell       Date:  2009-06-12       Impact factor: 41.582

4.  EZH2 Y641 mutations in follicular lymphoma.

Authors:  C Bödör; C O'Riain; D Wrench; J Matthews; S Iyengar; H Tayyib; M Calaminici; A Clear; S Iqbal; H Quentmeier; H G Drexler; S Montoto; A T Lister; J G Gribben; A Matolcsy; J Fitzgibbon
Journal:  Leukemia       Date:  2011-01-14       Impact factor: 11.528

5.  TCL1 oncogene expression in B cell subsets from lymphoid hyperplasia and distinct classes of B cell lymphoma.

Authors:  J W Said; K K Hoyer; S W French; L Rosenfelt; M Garcia-Lloret; P J Koh; T C Cheng; G G Sulur; G S Pinkus; W M Kuehl; D J Rawlings; R Wall; M A Teitell
Journal:  Lab Invest       Date:  2001-04       Impact factor: 5.662

6.  microRNA expression profile and identification of miR-29 as a prognostic marker and pathogenetic factor by targeting CDK6 in mantle cell lymphoma.

Authors:  Jian-Jun Zhao; Jianhong Lin; Tint Lwin; Hua Yang; Jianping Guo; William Kong; Sophie Dessureault; Lynn C Moscinski; Dorna Rezania; William S Dalton; Eduardo Sotomayor; Jianguo Tao; Jin Q Cheng
Journal:  Blood       Date:  2010-01-19       Impact factor: 22.113

7.  MicroRNA signatures characterize diffuse large B-cell lymphomas and follicular lymphomas.

Authors:  Anja Roehle; Kai P Hoefig; Dirk Repsilber; Christoph Thorns; Marita Ziepert; Kai O Wesche; Marlen Thiere; Markus Loeffler; Wolfram Klapper; Michael Pfreundschuh; András Matolcsy; Heinz-Wolfram Bernd; Lila Reiniger; Hartmut Merz; Alfred C Feller
Journal:  Br J Haematol       Date:  2008-06-03       Impact factor: 6.998

8.  Follicular lymphomas with and without translocation t(14;18) differ in gene expression profiles and genetic alterations.

Authors:  Ellen Leich; Itziar Salaverria; Silvia Bea; Andreas Zettl; George Wright; Victor Moreno; Randy D Gascoyne; Wing-Chung Chan; Rita M Braziel; Lisa M Rimsza; Dennis D Weisenburger; Jan Delabie; Elaine S Jaffe; Andrew Lister; Jude Fitzgibbon; Louis M Staudt; Elena M Hartmann; Hans-Konrad Mueller-Hermelink; Elias Campo; German Ott; Andreas Rosenwald
Journal:  Blood       Date:  2009-05-26       Impact factor: 22.113

9.  The DLEU2/miR-15a/16-1 cluster controls B cell proliferation and its deletion leads to chronic lymphocytic leukemia.

Authors:  Ulf Klein; Marie Lia; Marta Crespo; Rachael Siegel; Qiong Shen; Tongwei Mo; Alberto Ambesi-Impiombato; Andrea Califano; Anna Migliazza; Govind Bhagat; Riccardo Dalla-Favera
Journal:  Cancer Cell       Date:  2010-01-07       Impact factor: 31.743

10.  A mammalian microRNA expression atlas based on small RNA library sequencing.

Authors:  Pablo Landgraf; Mirabela Rusu; Robert Sheridan; Alain Sewer; Nicola Iovino; Alexei Aravin; Sébastien Pfeffer; Amanda Rice; Alice O Kamphorst; Markus Landthaler; Carolina Lin; Nicholas D Socci; Leandro Hermida; Valerio Fulci; Sabina Chiaretti; Robin Foà; Julia Schliwka; Uta Fuchs; Astrid Novosel; Roman-Ulrich Müller; Bernhard Schermer; Ute Bissels; Jason Inman; Quang Phan; Minchen Chien; David B Weir; Ruchi Choksi; Gabriella De Vita; Daniela Frezzetti; Hans-Ingo Trompeter; Veit Hornung; Grace Teng; Gunther Hartmann; Miklos Palkovits; Roberto Di Lauro; Peter Wernet; Giuseppe Macino; Charles E Rogler; James W Nagle; Jingyue Ju; F Nina Papavasiliou; Thomas Benzing; Peter Lichter; Wayne Tam; Michael J Brownstein; Andreas Bosio; Arndt Borkhardt; James J Russo; Chris Sander; Mihaela Zavolan; Thomas Tuschl
Journal:  Cell       Date:  2007-06-29       Impact factor: 41.582

View more
  31 in total

1.  MicroRNAs and Glucocorticoid-Induced Apoptosis in Lymphoid Malignancies.

Authors:  Ronit Vogt Sionov
Journal:  ISRN Hematol       Date:  2013-01-29

2.  Colocalization of BCL2-positive and -negative follicular lymphoma.

Authors:  C Laurent; P Brousset
Journal:  Leukemia       Date:  2014-01-27       Impact factor: 11.528

3.  Differences between BCL2-break positive and negative follicular lymphoma unraveled by whole-exome sequencing.

Authors:  A Zamò; J Pischimarov; M Schlesner; P Rosenstiel; R Bomben; H Horn; T Grieb; T Nedeva; C López; A Haake; J Richter; L Trümper; C Lawerenz; W Klapper; P Möller; M Hummel; D Lenze; M Szczepanowski; L Flossbach; M Schreder; V Gattei; G Ott; R Siebert; A Rosenwald; E Leich
Journal:  Leukemia       Date:  2017-08-21       Impact factor: 11.528

4.  Similar clinical features in follicular lymphomas with and without breaks in the BCL2 locus.

Authors:  E Leich; E Hoster; M Wartenberg; M Unterhalt; R Siebert; K Koch; W Klapper; M Engelhard; B Puppe; H Horn; A M Staiger; C Stuhlmann-Laeisz; H W Bernd; A C Feller; M Hummel; D Lenze; H Stein; S Hartmann; M L Hansmann; P Möller; W Hiddemann; M Dreyling; G Ott; A Rosenwald
Journal:  Leukemia       Date:  2015-12-01       Impact factor: 11.528

5.  Identification of the SOX5 gene as a novel IGH-involved translocation partner in BCL2-negative follicular lymphoma with t(12;14)(p12.2;q32).

Authors:  Masayuki Shiseki; Akihiro Masuda; Kentaro Yoshinaga; Naoki Mori; Michiko Okada; Toshiko Motoji; Junji Tanaka
Journal:  Int J Hematol       Date:  2015-06-27       Impact factor: 2.490

6.  Follicular lymphoma t(14;18)-negative is genetically a heterogeneous disease.

Authors:  Dominik Nann; Joan Enric Ramis-Zaldivar; Inga Müller; Blanca Gonzalez-Farre; Janine Schmidt; Caoimhe Egan; Julia Salmeron-Villalobos; Guillem Clot; Sven Mattern; Franziska Otto; Barbara Mankel; Dolors Colomer; Olga Balagué; Vanessa Szablewski; Carmen Lome-Maldonado; Lorenzo Leoncini; Stefan Dojcinov; Andreas Chott; Christiane Copie-Bergman; Irina Bonzheim; Falko Fend; Elaine S Jaffe; Elias Campo; Itziar Salaverria; Leticia Quintanilla-Martinez
Journal:  Blood Adv       Date:  2020-11-24

Review 7.  Indolent lymphomas in the pediatric population: follicular lymphoma, IRF4/MUM1+ lymphoma, nodal marginal zone lymphoma and chronic lymphocytic leukemia.

Authors:  Leticia Quintanilla-Martinez; Birgitta Sander; John K C Chan; Luc Xerri; German Ott; Elias Campo; Steven H Swerdlow
Journal:  Virchows Arch       Date:  2015-09-28       Impact factor: 4.064

8.  Genome-wide copy-number analyses reveal genomic abnormalities involved in transformation of follicular lymphoma.

Authors:  Alyssa Bouska; Timothy W McKeithan; Karen E Deffenbacher; Cynthia Lachel; George W Wright; Javeed Iqbal; Lynette M Smith; Weiwei Zhang; Can Kucuk; Andrea Rinaldi; Francesco Bertoni; Jude Fitzgibbon; Kai Fu; Dennis D Weisenburger; Timothy C Greiner; Bhavana J Dave; Randy D Gascoyne; Andreas Rosenwald; German Ott; Elias Campo; Lisa M Rimsza; Jan Delabie; Elaine S Jaffe; Rita M Braziel; Joseph M Connors; Louis M Staudt; Wing-Chung Chan
Journal:  Blood       Date:  2013-09-13       Impact factor: 22.113

9.  Predicting miRNA-Disease Association Based on Modularity Preserving Heterogeneous Network Embedding.

Authors:  Wei Peng; Jielin Du; Wei Dai; Wei Lan
Journal:  Front Cell Dev Biol       Date:  2021-06-10

10.  miR-29 modulates CD40 signaling in chronic lymphocytic leukemia by targeting TRAF4: an axis affected by BCR inhibitors.

Authors:  Sonali Sharma; Gabriela Mladonicka Pavlasova; Vaclav Seda; Katerina Amruz Cerna; Eva Vojackova; Daniel Filip; Laura Ondrisova; Veronika Sandova; Lenka Kostalova; Pedro F Zeni; Marek Borsky; Jan Oppelt; Kvetoslava Liskova; Leos Kren; Andrea Janikova; Sarka Pospisilova; Stacey M Fernandes; Medhat Shehata; Laura Z Rassenti; Ulrich Jaeger; Michael Doubek; Matthew S Davids; Jennifer R Brown; Jiri Mayer; Thomas J Kipps; Marek Mraz
Journal:  Blood       Date:  2021-05-06       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.